Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 17, 2015

Primary Completion Date

March 14, 2017

Study Completion Date

March 14, 2017

Conditions

Hypertension, Pulmonary

Interventions

DRUG

[11C]-GSK2256098 500 MBq

\[11C\]-GSK2256098 injection will be provided as IV infusion, 20 mL, containing up to 5% ethanol in saline.

Trial Locations (2)

GSK Investigational Site, London

GSK Investigational Site, London